Standard BioTools Inc. (NASDAQ:LAB) Director Purchases $5,110,216.54 in Stock

Standard BioTools Inc. (NASDAQ:LAB) Director Casdin Partners Master Fund, L bought 4,820,959 shares of the stock in a transaction dated Friday, February 28th. The stock was purchased at an average price of $1.06 per share, with a total value of $5,110,216.54. Following the purchase, the director now owns 58,846,780 shares in the company, valued at $62,377,586.80. This trade represents a 8.92 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Standard BioTools Price Performance

Shares of NASDAQ LAB opened at $1.20 on Thursday. The stock has a market cap of $446.71 million, a P/E ratio of -1.69 and a beta of 1.57. Standard BioTools Inc. has a 1 year low of $0.99 and a 1 year high of $3.04. The firm has a 50-day moving average of $1.56 and a 200 day moving average of $1.79.

Wall Street Analyst Weigh In

Separately, KeyCorp cut Standard BioTools from an “overweight” rating to a “sector weight” rating in a research note on Thursday, February 27th.

Hedge Funds Weigh In On Standard BioTools

Several large investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Standard BioTools by 4.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 168,777 shares of the company’s stock worth $295,000 after buying an additional 7,304 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Standard BioTools by 7.7% in the third quarter. JPMorgan Chase & Co. now owns 139,748 shares of the company’s stock worth $270,000 after acquiring an additional 9,995 shares in the last quarter. HighTower Advisors LLC boosted its holdings in Standard BioTools by 13.0% in the fourth quarter. HighTower Advisors LLC now owns 92,791 shares of the company’s stock worth $162,000 after acquiring an additional 10,690 shares in the last quarter. Invesco Ltd. grew its stake in shares of Standard BioTools by 7.5% in the fourth quarter. Invesco Ltd. now owns 175,041 shares of the company’s stock worth $306,000 after acquiring an additional 12,194 shares during the last quarter. Finally, Wolverine Trading LLC bought a new position in shares of Standard BioTools during the third quarter valued at $27,000. 53.74% of the stock is currently owned by hedge funds and other institutional investors.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.